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Primary Objective. To test the hypothesis that two injections of enzyme-potentiated mosquito antigen signiﬁcantly reduce
the size of experimental mosquito bites in participants with LLR-MB. Design. Randomised, double-blind, placebo-controlled,
parallel group comparison over 3 months. Setting. Hospital outpatient clinic. Participants. Fifty adult participants of both sexes.
Interventions. Two injections of mosquito antigen or matching placebo, 6 weeks apart. Main Outcome Measures. Early (1 hour) and
late (24 hours) mean square root of erythema area (SREA) following controlled mosquito bite with the second bite given at least 6
weeks following the ﬁnal injection. Results. At 1 hour, mean SREA was slightly higher in the EPD group compared to placebo after
adjusting for baseline values (0.46, 95% CI−6.11 to 7.03), but this was not statistically signiﬁcant (P = 0.89, ANCOVA analysis);
neither were the results at 24 hours (−2.58, 95% CI−11.73 to 6.57) (P = 0.57). The proportion of participants experiencing a
decrease in wheal size at 1 or 24 hours was similar between groups. Conclusions. EPD was not demonstrated to be eﬀective for
immediate or delayed LLR-MB. Methodological problems included a high variability in LLR-MB between subjects, suggesting that
a crossover design should be used in future.
1.Introduction
Large local reactions to mosquito bites (LLR-MB) are
common and sometimes distressing and may be immediate,
delayed, or both [1]. The mechanism is still controversial,
with some authors favouring an IgE- or IgG4-mediated
allergic process [2, 3] and others a lymphoproliferative
process [4]. Although clinical studies have demonstrated the
eﬀectivenessofantihistaminesasanacutetreatmentforLLR-
MB [5], conventional speciﬁc immunotherapy has not been
generally used. This is presumably because, in contrast to
wasp or bee stings, mosquito bites almost never cause life-
threatening reactions [6].
Enzyme-potentiated desensitisation (EPD) is a thera-
peutic technique in use for 30 years [7–10]i nw h i c h
low-dose allergens (10−12 mmol/L, comparable to skin prick
test doses) are given intradermally in combination with
the enzyme beta-glucuronidase, which is used to enhance
the desensitising eﬀect of the low-dose allergen. Prospective
audit has demonstrated EPD to be safer than conventional
immunotherapy [11] with no reports of systemic allergic
reactions. Personal clinical experience and an unpublished
survey of EPD users suggested beneﬁcial results of an EPD
mosquito antigen product in clinical use for several years
for LLR-MB. The relative safety and apparent eﬀectiveness of
EPD as a preventative approach prompted the present study.
Several small but poorly reported RCTs using EPD
based on mixed inhalant allergens suggested eﬀectiveness in
seasonal allergic rhinitis due to grass pollen [12–15]a n d
childhoodhousedustmiteallergy[16],althoughalargerand2 Journal of Allergy
more fully reported clinical trial failed to conﬁrm the results
for seasonal allergic rhinitis [17]. Single studies have shown
positive results using mixed food allergens for childhood
attention deﬁcit disorder [18] and childhood migraine [19].
The putative mechanism of action of EPD is unclear. It does
not have an eﬀect on B-cell immunity or generate “blocking”
antibody nor does it alter skin prick test results or speciﬁc
IgE levels [16]. However, it has been shown to alter cytokines
involved with the immune response such as IL-6 and IL-10
[20].
The objective of the study was to test the hypothesis
that two injections of EPD mosquito antigen would result
in a reduced erythema area after controlled mosquito bite
c h a l l e n g ei nag r o u po fa d u l ts u ﬀerers of LLR-MB, when
compared against a similar group given placebo injections.
As a pilot study, we also aimed to test the methodology and
provide estimates for a sample size calculation to power a
deﬁnitive study if the results proved encouraging.
2.MaterialsandMethods
The study was conducted in accordance with the Declaration
of Helsinki [21]. The study was conducted with the under-
standing and the written informed consent of the subjects.
The study was approved by the Joint University College Lon-
don Hospitals/University CollegeLondon EthicsCommittee.
50participantswererecruitedinLondonfromadatabase
kept by one of the authors (N. Hill) of LLR-MB suﬀerers
who had participated in previous clinical studies of topical
antibite agents. Most were employees at the London School
of Hygiene and Tropical Medicine. Mosquito challenge was
performed there by NH and EPD injections were performed
at the Royal London Homeopathic Hospital outpatient
department by S. Berkovitz. Participants were recruited from
March to July 2003 and were not followed up beyond their
ﬁnal mosquito exposure, the last of which was performed in
January 2004.
In order to be candidates for inclusion, participants had
to be aged between 18 and 65, of either sex, with a diagnosis
ofLLR-MBdeterminedby(1)ahistoryoflargelocalreaction
after insect bite identiﬁed as mosquito by participants, (2)
mean erythema diameter (ED) of 20mm or greater within
24h of ﬁrst experimental challenge to mosquito bite (for
details see below). They were not admitted to the study if any
of the following criteria were present: (1) previous treatment
with EPD, (2) treatment with conventional immunotherapy
in the last 5 years, (3) history of anaphylaxis or laryngeal
oedema, (4) moderate-to-severe asthma (as judged by caus-
ing nocturnal waking, emergency hospital attendance in last
twelve months, or need for systemic steroid treatment in last
twelve months), (5) currently pregnant or breast feeding, (6)
severeskindiseaseorpigmentationmakingthemeasurement
of erythema diﬃcult (this excluded participants of Negroid
or other dark skin type), (7) chronic severe urticaria or
dermatographism, (8) use of regular oral antihistamine,
non-steroidal anti-inﬂammatory drugs, oral steroids, or
immunosuppressants, (9) concomitant serious illness or
cardiovascular or respiratory disease requiring specialist care
or drug treatment (other than essential hypertension or
mild asthma); or (10) any other condition that in the
investigators’opinionexcludedtheparticipantongroundsof
safety.
Participants were randomised to receive two injections
of mosquito antigen or placebo at an interval of six-to-
eight weeks, the ﬁrst no less than a week after the ﬁrst
mosquito exposure. Blocked randomisation was performed
with random block sizes with the investigators blinded
to the allocation list. Individualised EPD vials were kept
refrigerated or in a thermos ﬂask ﬁlled with iced water.
EPD was supplied as sterilised individual vials containing
mosquito antigen (extract of crushed laboratory-bred female
Aedes Aegypti mosquito heads in buﬀer solution, containing
approximately 120fg of salivary gland per 0.04mL) or
placebo (an identical buﬀer solution without mosquito
antigen). 0.04mL of mosquito antigen or placebo was drawn
up by the Gilman pipette and mixed with 0.01mL of beta-
glucuronidase (Seravac, 1500–2000 Fishman units/mL). The
resulting 0.05mL was drawn up in an insulin syringe and
administered by intradermal injection into the ﬂexor aspect
of the forearm. All EPD vials were prepared by McEwen
Laboratories, Pangbourne (details of the method of prepara-
tion are available from S. Berkovitz) and administered by S.
Berkovitz whohad severalyears’experience in the technique.
Participants waited one hour after the ﬁrst injection and half
an hour after the second injection to ensure the absence of
immediate adverse eﬀects. They were asked to not to observe
the immediate reaction to maintain blinding. They were
given a questionnaire to post back after 24 hours to ascertain
any delayed adverse eﬀects and to report the presence and
size of any swelling at the injection site (a possible cause for
unblinding) and any itching.
The primary outcome measure was the square root of
erythema area measured at 1 hour (T1) and 24 hours (T24)
after mosquito exposure. A secondary outcome measure was
the degree of itching at T0 and T24. Erythema area has been
used by N. Hill in previous studies of topical antipruritics for
mosquito bites and has been found to be a reliable measure.
The square root transformation was used to satisfy statistical
assumptions (normality).
Participants were all subjected to an initial mosquito
exposure to conﬁrm their eligibility for the study and again
six-to-eight weeks following the second EPD injection. The
method was as follows. Female (3-4 day old) Aedes aegypti
mosquitos were starved for 24 hours prior to use. Per daily
period, the mosquitoes were isolated singly in small plastic
tubes closed by netting to prevent escape whilst enabling
them to feed through the netting.
The participants’ forearms were cleaned with 70%
ethanol and allowed to dry. Each subject was exposed to
a single Aedes aegypti mosquito bite. A mosquito tube was
secured on the midpoint of the nondominant forearm and
allowed to feed for 10 minutes. At the end of this period, the
feeding status of the mosquito (fed, partially fed, unfed) was
noted. If a mosquito was not observed to be feeding after 5
minutes, it was replaced by another. In addition, the number
of probes (the places where the mosquito penetrates the skin
to ﬁnd a good blood source) was recorded, since saliva could
be injected even if no blood is extracted.Journal of Allergy 3
50 participants
randomised
25 allocated to mosquito injection 25 allocated to placebo injection
1 lost to followup (broken ankle-
given analgesic medication not
permitted in study)
0 lost to followup
24 analysed 25 analysed
Figure 1: Participant ﬂow.
The diameter of erythema was measured with a digital
calliper (Mitutoyo Digimatic Calliper, 500-311). Erythema
length and width were deﬁned as the maximum diameter
and orthogonal diameter, respectively, (in millimetres).
Erythema area (EA) was calculated as the area of an
ellipse with these diameters (in millimetres squared). If
there was more than one erythematous bite, the largest
was used for the measurement. All calliper measurements
were performed by the same person throughout the study.
Diameter measurements were made at 15 minutes (T0), 1
hour (T1), 24 hours (T24).
Participants were not permitted any symptomatic med-
ication following mosquito exposure until 24 hours after
exposure (the time of the ﬁnal measurement of erythema
diameter). They were allowed to use topically applied
ice packs for symptomatic relief. Regular medication was
permitted as usual.
With no previous studies of EPD or similar treatments
in this condition on which, to base a power calculation, an
approximate calculation, using ANCOVA methodology, was
performed using data from a similar group of participants
in a previous study of a mosquito repellent. To have an 80%
chance of detecting as signiﬁcant using a two-sample t-test
(at the 5% level), a 45% reduction in erythema area after
verum treatment with no change in the placebo group, with
an assumed baseline mean area of 1206mm2 and a standard
deviation of 772mm2, 33 participants were required in each
group. We decided to recruit 25 participants in each group
since we were not performing a deﬁnitive study. However
we note that the latter sample size actually has 94% power
to detect such as diﬀerence using analysis of covariance
(ANCOVA), assuming a correlation of 0.7 between the
pretreatment and posttreatment responses and no loss to
followup. ANCOVA was used to analyse the results on an
intention-to-treat basis, comparing the posttreatment wheal
size adjusted for the pretreatment wheal size between EPD
and placebo.
Randomisation to verum or placebo groups was per-
formed by the trial statistician using block randomisation
with blocks of random size. The code was posted to McEwen
Laboratories in Pangbourne, the company supplying the
EPD vials, and to no one else. Prior to delivery of vials
to London, they labelled the identical vials with sequential
numbers (1–50) according to the allocation sequence and
placed them in two boxes (one for the ﬁrst and one for the
second injection). There was no further contact between the
laboratory and any of the investigators for the duration of
the trial. After enrolment and ﬁrst mosquito exposure by
N. Hill, S. Berkovitz allocated the next available number at
each subject’s ﬁrst EPD injection. The code was only revealed
to the researchers once recruitment and data collection
were complete, and data analysis was proceeding. All study
personnel and participants were not aware of treatment
assignmentthroughoutthestudy.However,participantsmay
have become inadvertently unblinded because of prolonged
swellingoritchingatthesiteofinjectionafterEPDcompared
to placebo at 24 hours. This was explored using a participant
questionnaire ﬁlled out at 24 hours after each injection and
returned by post to the investigators.
3. Results
Participant ﬂow is shown in Figure 1. One patient in the
mosquito injection group was lost to followup; thus data
from 49 participants were available for the intention-to-treat
analysis. Therefore, all participants who underwent random
allocation were analyzed according to group assignment.
One other patient violated the protocol as they had received
thewrongvialinerrorbut,sincebothvialswereplacebo,this
was thought unlikely to aﬀect the results. Baseline data are
displayed in Table 1, showing good comparability between
groups.
Primary outcomes are summarised in Table 2.A t1h o u r
following bite, mean SREA was slightly higher in the EPD4 Journal of Allergy
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Figure 2: Scatter plots illustrating individual participants’ results. (a) Results at one hour after mosquito bite exposure. (b) Results at 24
hours after mosquito bite exposure.
group compared to the placebo group after adjusting for
baselinevalues(0.46,95%conﬁdenceinterval −6.11to7.03),
but this was not close to statistical signiﬁcance suggesting
little evidence of any eﬀect attributable to EPD (P =
0.89, ANCOVA analysis). Both groups decreased slightly
compared to their baseline values. Likewise, at 24 hours
after bite, mean SREA was slightly lower in the EPD group
compared to the placebo group after adjusting for baseline
values (−2.58, 95% CI −11.73 to 6.57), but again this was
not statistically signiﬁcant (P = 0.57). This time both groups
increased compared to their baseline values. The proportion
of participants experiencing a decrease in wheal size was
similar for EPD and placebo and not one likely to prove
clinically useful.
Wethenrestrictedtheanalysistopatientswhohadexhib-
ited exposure diameters exceeding 50mm in the baseline
measures. There were 23 patients in this subgroup (8 on
placebo and 15 on drug). Repeating the ANCOVA analyses
for the 1 hour and 24 hour data led to no diﬀerence in
the conclusions. The estimates were 1 hour: −0.54 (−12.20
to 11.12, P = 0.92) and 24 hour: 7.02 (−9.70 to 23.73,
P = 0.39). Although there is an imbalance (by chance) in the
numbers in the subgroup analysis, the ANCOVA does take
account of baseline measures.
For the secondary outcome, that of itching at the time of
controlled bite and 24 hours afterwards, the results are given
in Table 3. A larger proportion of participants experienced a
reduction in itching at the time of bite with EPD, whereas
at 24 hours after bite there was a larger proportion with
placebo. In neither case was there a statistically signiﬁcant
diﬀerence between groups.
Success of blinding was indirectly estimated by analysing
the proportion of participants who noticed itch or swelling
associated with the injection. For the EPD participants,
41/50 injections produced swelling noticeable to the partic-
ipants 24 hours after the injection, with a mean diameter
(patient-measured using a ruler) of 6.4mm. For the placebo
Table 1: Baseline data.
Characteristic Mosquito injection
group (n = 25)
Placebo group
(n = 25)
Mean age (±SD) 37.26 (8.32) 37.17 (8.23)
Sex (F/M) 19/5 22/3
History of atopic disease 12 12
Previous desensitization 2 1
On regular medication 6 10
Perceived severity of previous
reactions (0–3; 0 = mild, 3 =
severe)
00 00
11 11
21 9 21 9
33 32
Missing data 2 Missing data 3
Perceived duration of previous
reactions (1–5; 1 = less than
an hour, 5 = greater than 24
hours)
10 11
20 23
31 31
44 45
51 9 51 6
Missing data 1
participants, only 11/48 injections produced such a reaction,
with a mean diameter of 8.5mm. This might indicate some
degree of unblinding, since persistent swelling might lead
participants to conclude (correctly) that they had received
verum. One participants’ data was missing. However, only
two participants complained of itching at 24 hours, both in
the placebo group.
Only two adverse eﬀects occurred other than expected
local reactions. Both of these occurred in the placebo group.
One patient sustained myalgia lasting a few hours; the otherJournal of Allergy 5
Table 2: Results for primary outcome measure, the mean square root of erythema area (SREA) at 1 hours and 24 hours post-bite.
Outcome Mean (SE) of SREA (mm)
Mosquito antigen (n = 24)
Mean (SE) of SREA (mm)
Placebo (n = 25)
Diﬀerence in mean SREA
(drug-placebo)∗ (95% CI) P
Baseline
1 hour 31.3 (3.4) 24.5 (3.2)
24 hours 33.7 (3.4) 28.7 (2.3)
Followup
1 hour 27.4 (2.9) 22.6 (3.2) 0.46 (−6.11 to 7.03) 0.89
24 hours 35.1 (2.4) 35.0 (2.9) −2.58 (−11.73 to 6.57) 0.57
Proportion of participants
with a decrease in SREA at
1 hour 14/24 (58%) 12/25 (48%)
24 hours 8/24 (33%) 9/25 (36%)
∗Adjusted for baseline values (ANCOVA analysis).
Table 3: Results for secondary outcome measure, change in itching
at time of bite and 24 hours afterwards.
Proportion of participants
with a reduction in itching
EPD Placebo P∗
Time of bite 9/24 (38%) 13/25 (52%) 0.31
24 hours after bite 14/24 (58%) 11/25 (44%) 0.32
∗Chi-squared test.
had a mild vasovagal episode 10 minutes following the
injection.
4. Discussion
The disappointing results contrast with a retrospective audit
of 11 practitioners carried out by the ﬁrst author prior to
the study. This documented 53 patients, of whom 83% were
said to have achieved a moderate or great improvement
after two EPD injections of mosquito antigen. The most
likely reason for the discrepancy is observer bias in everyday
practice. Another possible but unlikely reason is that we
gave injections at 6 weekly intervals (due to time pressure),
whereas the recommended interval is 8–12 weeks. Since the
native mosquito extract was not analysed or standardised for
allergen content, the exact amount of administered antigen
is unknown and likely to show batch-to-batch variation.
Therefore, it is possible that a higher dose might have
produced a better clinical eﬀect, although by deﬁnition EPD
is a “low-dose” treatment.
A noteworthy feature of the controlled mosquito bites
is the high variation between participants suggesting that a
cross-overtrialmightbeappropriateforfuturestudiesinthis
area. Also, there is relatively high intraparticipant variability
in the placebo group over a few months, with erythema di-
ametersvaryingbyafactorofupto2andthereforeerythema
area by a factor of up to 4. Scatter plots (Figures 2(a) and
2(b)) illustrate both the sources of variation and suggest that
relatively large numbers of patients would be required for a
deﬁnitive study, had the results of our pilot showed a trend
towards eﬃcacy (which was not the case).
5. Conclusion
This pilot study suggests that EPD, although safe, is not of
value in preventing large local reactions to mosquito bites
or the itching associated with them, and that a larger study
would not be worth performing. Methodological problems
to note include a high variability in LLR-MB across subjects,
suggesting that a cross-over trial design should be used for
further studies of this condition.
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